BDSI Profile
BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical campany that develops and commercializes novel treatments for chronic pain and other conditions. The company's products use proprietary drug delivery technologies to improve the efficacy and safety of existing drugs.
BDSI's flagship product is Belbuca, a buccal film formulation of the opioid analgesic buprenorphine, which is used to treat chronic pain. The company also markets and develops other products, including Bunavail, a buprenorphine and naloxone sublingual film for the treatment of opioid dependence, and Onsolis, a fentanyl buccal soluble film for breakthrough cancer pain.
BDSI was founded in 1997 and is headquartered in Raleigh, North Carolina. The company has a strong research and development program and has collaborations with other pharmaceutical companies and academic institutions to advance its product pipeline.
As of February 2023, BioDelivery Sciences International, Inc. is still an active company, and its stock is traded on the NASDAQ stock exchange under the ticker symbol BDSI. The company's focus on developing novel treatments for chronic pain and other conditions, combined with its expertise in drug delivery technologies, makes it a leader in the specialty pharmaceutical industry.
|
